Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20384682 | 0.87 | PAOX (0.40) | SIGMAR1PAOXUSP2ALDH1A1CSNK2A2 | |
| SCHEMBL18708827 | 0.86 | SIGMAR1 (0.33) | SIGMAR1USP2ALDH1A1KDM4E | |
| SCHEMBL21120546 | 0.85 | PAOX (0.43) | SIGMAR1PAOXUSP2ALDH1A1CSNK2A2 | |
| SCHEMBL22857505 | 0.84 | TSHR (0.36) | SIGMAR1PAOXUSP2ALDH1A1HTR1A | |
| SCHEMBL10041869 | 0.84 | CARM1 (0.39) | ALDH1A1KDM4E | |
| SCHEMBL7290324 | 0.82 | HRH3 (0.42) | ALDH1A1 | |
| SCHEMBL25623721 | 0.79 | HSD11B1 (0.36) | USP2ALDH1A1 | |
| SCHEMBL24713588 | 0.79 | KDM4E (0.42) | SIGMAR1USP2ALDH1A1HTR1AMC4R | |
| SCHEMBL21779744 | 0.79 | SIGMAR1 (0.36) | SIGMAR1PAOXUSP2MC4RKDM4E | |
| SCHEMBL22550677 | 0.79 | KDM4E (0.42) | SIGMAR1USP2ALDH1A1HTR1AMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-10752705-B2 | Oligosaccharide compositions and methods for producing thereof | CADENA BIO, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| WO-2018058029-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-9884863-B2 | STAT3 inhibitor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-02-06 | — | — | US | disclosed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170152260-A1 | STAT3 INHIBITOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152260-A1 | STAT3 INHIBITOR | STAT3, STAT1, STAT4 | SIGMAR1 4216/4885PAOX 2082/4885USP2 1812/4885 |
| US-10752705-B2 | Oligosaccharide compositions and methods for producing thereof | OSTC, FUT5, FUT6 | SIGMAR1 4360/4885PAOX 345/4885USP2 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.